- Pacira is a first-mover in the lucrative non-opioid treatment market.
- In FY19 its bupivacaine / Depo-Foam slow release delivery technology combo Exparel made sales of ~$420m.
- The company has ambitious plans to turn Exparel into a blockbuster by 2025, whilst adding $200m from sales of its cold-therapy treatment Iovera.
- New markets are being targeted in women's health, sports injuries, pediatrics, and lower-extremity surgeries, as well as overseas.
- I set a price target for Pacira stock in February of $60, which the company has met. If things continue to click for Pacira - as I suspect they might - a triple-digit share price by FY21 is not unthinkable.
For further details see:
Pacira BioSciences: Products And Management Can Maintain Outperformance Despite Q2 Sales Decline